140 related articles for article (PubMed ID: 10214560)
1. Characterization of pharmacodynamic recession slopes for direct and indirect response models.
Krzyzanski W; Jusko WJ
J Pharmacokinet Biopharm; 1998 Aug; 26(4):409-36. PubMed ID: 10214560
[TBL] [Abstract][Full Text] [Related]
2. Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses.
Krzyzanski W; Jusko WJ
J Pharmacokinet Biopharm; 1997 Feb; 25(1):107-23. PubMed ID: 9353696
[TBL] [Abstract][Full Text] [Related]
3. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions.
Krzyzanski W; Jusko WJ
J Pharmacokinet Biopharm; 1998 Aug; 26(4):385-408. PubMed ID: 10214559
[TBL] [Abstract][Full Text] [Related]
4. Integrated functions for four basic models of indirect pharmacodynamic response.
Krzyzanski W; Jusko WJ
J Pharm Sci; 1998 Jan; 87(1):67-72. PubMed ID: 9452970
[TBL] [Abstract][Full Text] [Related]
5. Characterization of four basic models of indirect pharmacodynamic responses.
Sharma A; Jusko WJ
J Pharmacokinet Biopharm; 1996 Dec; 24(6):611-35. PubMed ID: 9300353
[TBL] [Abstract][Full Text] [Related]
6. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena.
Sharma A; Ebling WF; Jusko WJ
J Pharm Sci; 1998 Dec; 87(12):1577-84. PubMed ID: 10189270
[TBL] [Abstract][Full Text] [Related]
7. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition.
Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2001 Feb; 28(1):57-78. PubMed ID: 11253614
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
Ebling WF; Levy G
Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.
Trocóniz IF; Armenteros S; Planelles MV; Benítez J; Calvo R; Domínguez R
Clin Pharmacokinet; 2000 Jun; 38(6):505-18. PubMed ID: 10885587
[TBL] [Abstract][Full Text] [Related]
10. Assessment of drug interactions relevant to pharmacodynamic indirect response models.
Earp J; Krzyzanski W; Chakraborty A; Zamacona MK; Jusko WJ
J Pharmacokinet Pharmacodyn; 2004 Oct; 31(5):345-80. PubMed ID: 15669772
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.
Ren T; Zhu X; Jusko NM; Krzyzanski W; Jusko WJ
J Pharmacokinet Pharmacodyn; 2022 Oct; 49(5):493-510. PubMed ID: 36040645
[TBL] [Abstract][Full Text] [Related]
12. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
[TBL] [Abstract][Full Text] [Related]
13. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
14. Relationship between pharmacokinetic half-life and pharmacodynamic half-life in effect-time modeling.
Keller F; Czock D; Zellner D; Giehl M
Int J Clin Pharmacol Ther; 1998 Mar; 36(3):168-75. PubMed ID: 9562234
[TBL] [Abstract][Full Text] [Related]
15. Role of dosage regimen in controlling indirect pharmacodynamic responses.
Gobburu JV; Jusko WJ
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):45-57. PubMed ID: 11259832
[TBL] [Abstract][Full Text] [Related]
16. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
19. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
Tuk B; Danhof M; Mandema JW
J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic/pharmacodynamic model for recombinant human growth hormone effects on induction of insulin-like growth factor I in monkeys.
Sun YN; Lee HJ; Almon RR; Jusko WJ
J Pharmacol Exp Ther; 1999 Jun; 289(3):1523-32. PubMed ID: 10336548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
